Business Wire

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...

COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...
Psychology Today

4 Myths About Schizophrenia (and the Facts You Need to Know)

Roughly 1.1 percent of adults in the United States live with schizophrenia, according to the National Institute of Mental Health (NIMH). To put this into perspective, of the 52,964 people who visit ...
Seeking Alpha

Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...